factor V is resistant to inactivation by APC [4]. Several studies have demonstrated a relationship between the presence of APC resistance and an increased risk of venous thrombosis [9]. The FV Leiden allele is associated with a hypercoagulable state, which is reflected by increased levels of prothrombin activation fragments in plasma of individuals with inherited APC resistance [10]. The hypercoagulable state in carriers of FV Leiden mutation is explained by two mechanisms; In the first one APC cleavage site in FVa is lost, which impairs the normal degradation of FVa by APC [11]. The second observation is that FV Leiden is a poor APC cofactor in the degradation of FVIIIa because the cleavage at Arg506 is required for expression of APC cofactor activity of FV [12][13][14]. Molecular detection of FVL mutation could be achieved by different methodologies, the most common among them is PCR-RFLP [15].The Factor II (Prothrombin) mutation (20210G>A) is the second most common genetic defect associated with inherited venous thrombosis. The genetic variation (Guanine to Adenine transition at position 20210) in the 3'-untranslated region of the prothrombin gene had been associated with elevated blood levels of prothrombin which Keywords: Factor V Leiden; Prothrombin gene; Venous thromboembolism; Sudan
IntroductionVenous thromboembolic disease (VTE) is a term includes deep vein thrombosis (DVT) and pulmonary embolism (PE), or a combination of both. DVT is a common vascular condition that arises from the formation of a blood clot within the deep veins of the circulatory system. PE occurs when a segment of that thrombosis detaches or separates from the vein wall, travels through the bloodstream, and lodges in the pulmonary artery [1]. Venous thrombosis is a serious health problem causing significant morbidity and mortality. It may be fatal by its complication of pulmonary embolism Fatality rate of venous thrombosis is estimated at 1% to 2% [2,3]. The pathogenesis of venous thrombosis is including acquired and genetic risks factors. Acquired risk factors including pregnancy, oral contraceptive use, estrogen therapy, obesity, malignancy, diabetic mellitus, immobility, trauma and post operation can precipitate thrombosis. Genetic risk factors include the deficiency of protein C, protein S, antithrombin and mutations of factor V Leiden and Prothrombin gene [4,5]. Both of these genetic abnormalities are commonly found in patients with VTE, with prevalence varying between 20% and 50% for factor V Leiden and between 5% and 19% for prothrombin gene mutation [6]. Previous research indicated that the presence of factor V mutation increases risk for venous thrombosis 7-fold in heterozygotes and 80-fold in homozygotes [7]. The incidence of venous thrombosis in homozygotes is almost 100% and 10% in heterozygotes.
Material and Methods:This was descriptive Cross sectional study in which a total of 176 Sudanese subjects were enrolled in the period between July 2015 and July 2016. Among them, 38 apparently healthy Sudanese individuals as con...